Research programme: cancer radiotherapeutics - Algeta

Drug Profile

Research programme: cancer radiotherapeutics - Algeta

Alternative Names: 227Th conjugates; FGFR2-targeted thorium-227 conjugate; HER2-targeted thorium-227 conjugate; Targeted thorium conjugates - Algeta; TH-1 programme; thorium-227 conjugates; TTC - Algeta

Latest Information Update: 07 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Algeta
  • Developer Algeta; Norwegian Radium Hospital
  • Class Antibodies; Drug conjugates; Monoclonal antibodies; Peptides; Proteins; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Glutamate carboxypeptidase II inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Mar 2017 Preclinical development is ongoing in Norway
  • 17 Apr 2014 Lumiphore receives phase II SBIR grant from the US National Science Foundation for the development of cancer radiotherapeutics
  • 06 Mar 2014 Algeta has been acquired by Bayer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top